Literature DB >> 35848622

Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.

Carlos Camara-Lemarroy1, Luanne Metz2, Jens Kuhle3, David Leppert3, Eline Willemse3, David Kb Li4, Anthony Traboulsee5, Jamie Greenfield6, Graziela Cerchiaro6, Claudia Silva2, V Wee Yong2.   

Abstract

BACKGROUND: In the trial of Minocycline in Clinically Isolated Syndrome (MinoCIS), minocycline significantly reduced the risk of conversion to clinically definite multiple sclerosis (CDMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in MS, and minocycline modulates matrix metalloproteinases (MMPs).
OBJECTIVE: To assess the value of blood NfL and GFAP as a biomarker of baseline and future disease activity and its utility to monitor treatment response in minocycline-treated patients with clinically isolated syndrome (CIS).
METHODS: We measured NfL, GFAP, and MMPs in blood samples from 96 patients with CIS from the MinoCIS study and compared biomarkers with clinical and radiologic characteristics and outcome.
RESULTS: At baseline, NfL levels correlated with T2 lesion load and number of gadolinium-enhancing lesions. Baseline NfL levels predicted conversion into CDMS at month 6. GFAP levels at baseline were correlated with T2 lesion volume. Minocycline treatment significantly increased NfL levels at 3 months but not at 6 months, and decreased GFAP levels at month 6. Minocycline decreased MMP-7 concentrations at month 1. DISCUSSION: Blood NfL levels are associated with measures of disease activity in CIS and have prognostic value. Minocycline increased NfL levels at month 3, but reduced GFAP and MMP-7 levels.

Entities:  

Keywords:  CIS; GFAP; MMPs; Multiple sclerosis; NfL; minocycline

Mesh:

Substances:

Year:  2022        PMID: 35848622      PMCID: PMC9574233          DOI: 10.1177/13524585221109761

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   5.855


  27 in total

1.  Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis.

Authors:  Luanne M Metz
Journal:  Continuum (Minneap Minn)       Date:  2019-06

2.  The Role of Matrix Metalloproteinase 3 and 9 in the Pathogenesis of Acute Neuroinflammation. Implications for Disease Modifying Therapy.

Authors:  Srdjan Ljubisavljevic; I Stojanovic; J Basic; S Vojinovic; D Stojanov; G Djordjevic; D Pavlovic
Journal:  J Mol Neurosci       Date:  2015-02-22       Impact factor: 3.444

3.  Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosis.

Authors:  Carlos R Camara-Lemarroy; Claudia Silva; Luanne M Metz; Graziela Cerchiaro; Jamie Greenfield; Reza Dowlatabadi; Hans J Vogel; Chieh-Hsin Lee; Fabrizio Giuliani; Maryam Nakhaei-Nejad; David K B Li; Anthony Traboulsee; V Wee Yong
Journal:  Mult Scler Relat Disord       Date:  2021-02-03       Impact factor: 4.339

4.  Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.

Authors:  Marja Niiranen; Aleksi Kontkanen; Olli Jääskeläinen; Hanna-Mari Tertsunen; Tuomas Selander; Päivi Hartikainen; Nadine Huber; Eino Solje; Annakaisa Haapasalo; Tarja Kokkola; Tarja Lohioja; Sanna-Kaisa Herukka; Sakari Simula; Anne M Remes
Journal:  Mult Scler Relat Disord       Date:  2021-09-28       Impact factor: 4.339

Review 5.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

6.  Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.

Authors:  Claire Bridel; Cyra E Leurs; Zoë Y G J van Lierop; Zoé L E van Kempen; Iris Dekker; Harry A M Twaalfhoven; Bastiaan Moraal; Frederik Barkhof; Bernard M J Uitdehaag; Joep Killestein; Charlotte E Teunissen
Journal:  Neurology       Date:  2021-09-09       Impact factor: 9.910

7.  Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Authors:  Jens Kuhle; Harald Kropshofer; Dieter A Haering; Uma Kundu; Rolf Meinert; Christian Barro; Frank Dahlke; Davorka Tomic; David Leppert; Ludwig Kappos
Journal:  Neurology       Date:  2019-02-08       Impact factor: 9.910

8.  Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.

Authors:  Jens Kuhle; Nadia Daizadeh; Pascal Benkert; Aleksandra Maceski; Christian Barro; Zuzanna Michalak; Maria Pia Sormani; Jean Godin; Srinivas Shankara; Tarek A Samad; Alan Jacobs; Luke Chung; Nora Rӧsch; Carina Kaiser; Colin P Mitchell; David Leppert; Evis Havari; Ludwig Kappos
Journal:  Mult Scler       Date:  2021-08-11       Impact factor: 6.312

9.  Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.

Authors:  Tatiana Plavina; Carol M Singh; Dipen Sangurdekar; Carl de Moor; Bob Engle; Arie Gafson; Jaya Goyal; Elizabeth Fisher; Suzanne Szak; Revere P Kinkel; Alfred W Sandrock; Ray Su; Bernd C Kieseier; Richard A Rudick
Journal:  JAMA Netw Open       Date:  2020-11-02

10.  Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis.

Authors:  Simon Thebault; Hyunwoo Lee; Gauruv Bose; Daniel Tessier; Mohammad Abdoli; Marjorie Bowman; Jason Berard; Lisa Walker; Carolina A Rush; Heather MacLean; Ronald A Booth; Sridar Narayanan; Douglas L Arnold; Vincent Tabard-Cossa; Harold L Atkins; Amit Bar-Or; Mark S Freedman
Journal:  Ann Clin Transl Neurol       Date:  2020-04-18       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.